Open Access

High‑resolution melting analysis for rapid and sensitive MYD88 screening in chronic lymphocytic leukemia

Corrigendum in: /10.3892/ol.2019.10582

  • Authors:
    • Min Jiang
    • Jie Li
    • Jun Zhou
    • Chao Xing
    • Jing‑Jing Xu
    • Feng Guo
  • View Affiliations

  • Published online on: May 13, 2019     https://doi.org/10.3892/ol.2019.10342
  • Pages: 814-821
  • Copyright: © Jiang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

High resolution melting (HRM) assay is a novel technology for the fast, high‑throughput, sensitive, post‑PCR analysis of genetic mutations. Myeloid differentiation primary response 88 (MYD88) mutations are frequently reported in chronic lymphocytic leukemia (CLL) and confer a worse prognosis. The objective of the present study was to assess the value of HRM analysis for the rapid screening of MYD88 mutations in patients with CLL. Genomic DNA samples were extracted from the bone marrow of 129 newly diagnosed patients with CLL. A plasmid with an MYD88‑L265P mutation was constructed, and the p.L265P substitution, which is the predominant MYD88 mutation in CLL, was detected using HRM analysis and direct sequencing. The plasmid pCMV‑MYD88‑L265P‑Mu was successfully constructed as a positive control, and was verified by direct sequencing. The normalized and shifted melting curves of 6/129 (4.65%) samples were clearly different from those of other patients by HRM analysis. In addition, the 794T>C mutation in MYD88 was identified in 6 (4.65%) patients by direct sequencing. Sensitivity evaluation revealed that the HRM assay had a higher sensitivity (to 1% dilution) than direct sequencing, in addition to being convenient and time‑saving. The MYD88 p.L256P mutation has been implicated to be associated with adverse prognosis in CLL. HRM analysis has the potential to be a routine prescreening technique to identify the MYD88 p.L256P mutation and may facilitate the clinical treatment of CLL.
View Figures
View References

Related Articles

Journal Cover

July-2019
Volume 18 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Jiang M, Li J, Zhou J, Xing C, Xu JJ and Guo F: High‑resolution melting analysis for rapid and sensitive MYD88 screening in chronic lymphocytic leukemia Corrigendum in /10.3892/ol.2019.10582. Oncol Lett 18: 814-821, 2019.
APA
Jiang, M., Li, J., Zhou, J., Xing, C., Xu, J., & Guo, F. (2019). High‑resolution melting analysis for rapid and sensitive MYD88 screening in chronic lymphocytic leukemia Corrigendum in /10.3892/ol.2019.10582. Oncology Letters, 18, 814-821. https://doi.org/10.3892/ol.2019.10342
MLA
Jiang, M., Li, J., Zhou, J., Xing, C., Xu, J., Guo, F."High‑resolution melting analysis for rapid and sensitive MYD88 screening in chronic lymphocytic leukemia Corrigendum in /10.3892/ol.2019.10582". Oncology Letters 18.1 (2019): 814-821.
Chicago
Jiang, M., Li, J., Zhou, J., Xing, C., Xu, J., Guo, F."High‑resolution melting analysis for rapid and sensitive MYD88 screening in chronic lymphocytic leukemia Corrigendum in /10.3892/ol.2019.10582". Oncology Letters 18, no. 1 (2019): 814-821. https://doi.org/10.3892/ol.2019.10342